Table 2 Baseline characteristics of cases with later GCA diagnosis and controls, overall and stratified by sex
From: Apolipoproteins and the risk of giant cell arteritis—a nested case–control study
All | Women | Men | ||||
|---|---|---|---|---|---|---|
Cases | Controls | Cases | Controls | Cases | Controls | |
N | 100 | 400 | 81 | 324 | 19 | 76 |
Age; mean, years (SD) | 62.3 (6.6) | 61.9 (6.6) | 62.3 (6.7) | 61.9 (6.7) | 62.2 (6.1) | 61.7 (6.1) |
BMI; mean, kg/m2 (SD) | 25.0 (4.1) | 25.8 (3.9) | 24.4 (3.3) | 25.6 (4.0) | 27.3 (6.2) | 26.6 (3.5) |
Current smoking; n/N (%) | 16/92 (17) | 93/397 (23) | 14/73 (19) | 79/321 (25) | 2/19 (11) | 14/76 (18) |
Hypertension n/N (%) | 63/100 (63) | 274/398 (69) | 55/81 (68) | 220/323 (68) | 8/19 (42) | 54/75 (72) |
Lipid lowering drugs; n (%) | 2 (2) | 17 (4) | 2 (2) | 12 (4) | 0 | 5 (7) |
ApoA1; mean, mg/dL (SD) | 168.7 (29.1) | 160.9 (24.4) | 175.3 (27.0) | 164.5 (23.6) | 142.4 (21.6) | 145.0 (21.1) |
ApoB; mean, mg/dL (SD) | 109.3 (24.3) | 110.4 (27.8) | 111.4 (23.9) | 110.2 (29.0) | 100.9 (24.5) | 111.0 (21.9) |
ApoB/ApoA1; median (IQR) | 0.65 (0.53–0.78) | 0.67 (0.56–0.82) | 0.65 (0.53–0.75) | 0.66 (0.55–0.79) | 0.68 (0.55–0.93) | 0.76 (0.62–0.89) |
Waist; median, cm (IQR) | 76.0 (71.0–85.8) | 79.5 (72.0–88.8) | 75.0 (69.5–79.0) | 77.0 (70.0–85.0) | 93.0 (83.0–107.0) | 93.0 (86.0–101.0) |
Hip; median, cm (IQR) | 98.0 (91.0–101.0) | 98.0 (93.0–104.0) | 97.0 (91.0–100.0) | 97.0 (92.0–104.0) | 100.0 (97.0–105.0) | 99.0 (95.0–105.0) |
Waist/hip; median (IQR) | 0.79 (0.76–0.84) | 0.81 (0.77–0.87) | 0.78 (0.75–0.81) | 0.79 (0.75–0.83) | 0.94 (0.88–0.98) | 0.94 (0.91–0.97) |
Physical activity score median (IQR) | 6690 (4325–11,855) | 5850 (4238–10,865) | 6992 (4260–12,272) | 6720 (4190 –10,530) | 6180 4840–11,022 | 7862 (4666–12,877) |